AAAAAA
Results:
1-13
|
Results: 13
Authors:
Coleiro, B
Marshall, SE
Denton, CP
Howell, K
Blann, A
Welsh, KI
Black, CM
Citation: B. Coleiro et al., Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine, RHEUMATOLOG, 40(9), 2001, pp. 1038-1043
Authors:
MacGregor, AJ
Canavan, R
Knight, C
Denton, CP
Davar, J
Coghlan, J
Black, CM
Citation: Aj. Macgregor et al., Pulmonary hypertension in systemic sclerosis: risk factors for progressionand consequences for survival, RHEUMATOLOG, 40(4), 2001, pp. 453-459
Authors:
Tormey, VJ
Bunn, CC
Denton, CP
Black, CM
Citation: Vj. Tormey et al., Anti-fibrillarin antibodies in systemic sclerosis, RHEUMATOLOG, 40(10), 2001, pp. 1157-1162
Authors:
Denton, CP
Abraham, DJ
Citation: Cp. Denton et Dj. Abraham, Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis, CURR OP RH, 13(6), 2001, pp. 505-511
Authors:
Denton, CP
Black, CM
Citation: Cp. Denton et Cm. Black, Combination therapies for systemic sclerosis, SPR SEM IMM, 23(1-2), 2001, pp. 109-129
Authors:
Xu, SW
Denton, CP
Dashwood, MR
Holmes, AM
Bou-Gharios, G
Pearson, JD
Black, CM
Abraham, DJ
Citation: Sw. Xu et al., Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1, J INVES DER, 116(3), 2001, pp. 417-425
Authors:
Antoniv, TT
De Val, S
Wells, D
Denton, CP
Rabe, C
de Crombrugghe, B
Ramirez, F
Bou-Gharios, G
Citation: Tt. Antoniv et al., Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene, J BIOL CHEM, 276(24), 2001, pp. 21754-21764
Authors:
Denton, CP
Bing, Z
Xu, SW
Zhang, ZP
Bou-Gharios, G
Eberspaecher, H
Black, CM
de Crombrugghe, B
Citation: Cp. Denton et al., Activation of a fibroblast-specific enhancer of the Pro alpha 2(I) collagen gene in tight-skin mice, ARTH RHEUM, 44(3), 2001, pp. 712-722
Authors:
Denton, CP
Black, CM
Citation: Cp. Denton et Cm. Black, Scleroderma and related disorders: therapeutic aspects, BEST PR R C, 14(1), 2000, pp. 17-35
Authors:
Denton, CP
Howell, K
Stratton, RJ
Black, CM
Citation: Cp. Denton et al., Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study, CLIN EXP RH, 18(4), 2000, pp. 499-502
Authors:
Denton, CP
Bunce, TD
Dorado, MB
Roberts, Z
Wilson, H
Howell, K
Bruckdorfer, KR
Black, CM
Citation: Cp. Denton et al., Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon, RHEUMATOLOG, 38(4), 1999, pp. 309-315
Authors:
Black, CM
Silman, AJ
Herrick, AI
Denton, CP
Wilson, H
Newman, J
Pompon, L
Xu, SW
Citation: Cm. Black et al., Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma - Results of a randomized, double-blind, placebo-controlled trial, ARTH RHEUM, 42(2), 1999, pp. 299-305
Authors:
Dziadzio, M
Denton, CP
Smith, R
Howell, K
Blann, A
Bowers, E
Black, CM
Citation: M. Dziadzio et al., Losartan therapy for Raynaud's phenomenon and scleroderma - Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial, ARTH RHEUM, 42(12), 1999, pp. 2646-2655
Risultati:
1-13
|